Samsung Introduces Its Latest Radiology Innovations at RSNA 2020

Samsung to highlight its medical imaging portfolio with its latest radiology innovations in ultrasound, digital radiography and mobile computed tomography

Samsung at RSNA 2020: Contact in the Untact

CHICAGO--Samsung Electronics Co., Ltd. will showcase its premium diagnostic imaging solutions in ultrasound, digital radiography and mobile computed tomography at the Radiological Society of North America (RSNA) 2020 Annual Meeting from November 29 to December 5.

“This year has been a pivotal year for Samsung in moving forward new solutions across a variety of areas. We are looking forward to putting on display our advancements within ultrasound, digital radiography and mobile CT modalities,” stated Yongkwan Kim, Head of Health & Medical Equipment Business at Samsung Electronics and CEO of Samsung Medison. “Our innovative solutions demonstrate Samsung’s commitment to leveraging our innovation engine to better address the needs of healthcare providers and their patients.”

Ultrasound

Samsung will showcase the RS85 Prestige, which is designed to deliver outstanding scanning performance with consistent image clarity, depth of penetration and sensitivity to perfusion of blood flow to enhance abdominal and breast examination functionality. Above all, the RS85 Prestige delivers real-time images to clinicians, which is essential in ultrasound imaging.

New features:

• EzHRI™ assists in diagnosing fatty livers by showing the degree of the fatty liver after analyzing the ultrasound images and comparing the brightness level of the automatically selected location of hepatic parenchyma and renal cortex.
• TAI™ (Tissue Attenuation Imaging), TSI™ (Tissue Scatter distribution Imaging) provide quantitative tissue attenuation measurement and tissue scatter distribution measurement to assess steatotic liver changes.
• LA2-14A is an S-Vue Transducer™ with single crystal technology, providing clear distinction in images of anatomical structures based on high SNR and deep penetration. As a single crystal transducer added to the high-resolution imaging technology, Crystal Architecture™, useful images are provided for diagnosing thyroid and breast tumors as well as MSK tendon-related disorders.

Additional features deliver simplified workflow and accurate diagnoses:

• S-Detect™ simplifies breast examination processes by providing analysis of the selected lesion and standard reporting based on BI-RADS ATLAS* (Breast Imaging-Reporting and Data System, Atlas).
• S-Shearwave Imaging™ allows for non-invasive assessment of the stiffness of tissue/lesions in applications such as breast, liver, MSK and prostate, aided by color-coded elastogram, quantitative measurements, dual or single display options, and user-selectable ROI functions. It aids in the diagnosis of hepatocirrhosis and tumors.

Digital Radiography

Samsung is showcasing its premium digital mobile x-ray, the AccE GM85, which delivers unparalleled performance by improving diagnostic confidence and workflow. The AccE GM85, powered by a lithium-ion battery, in particular has demonstrated unprecedented performance during the recent pandemic. The AccE GM85 is suited to general imaging needs, and its practicality during the COVID-19 pandemic is highlighted through its unique feature set.

• Fast charging and long-lasting battery allows for a full charge within four hours, and the power to keep going all day without the need for additional charging. With Li-ion battery technology, it offers enhanced stability in wider temperature ranges and its lead-free composition is more friendly for the environment.
• SimGrid™ streamlines workflow and reduces the total exam time by 28% by omitting grid installation and removal from the conventional workflow.
• S-Vue™ provides better image quality and significantly reduces radiation dosage during exams. The dosage can be reduced by up to 45% for pediatric abdomen, 15.5% for pediatric chest, and 27% for pediatric skull exams with the new S-Vue™ engine¹.

Samsung will be introducing two new enhanced software options for its line of DR equipment, including:

• Value Up Package 2021, a suite of workflow enhancement and diagnostic tools for Samsung DR systems including an AI algorithm that automatically provides a heads-up view of chest AP/PA; enhanced S-Align function with information of tube and detector angle to DICOM; and many other tools to deliver improved clinical care.
• Mirror View, real-time wireless screen mirroring to a Smart TV or Miracast-enabled display for use within an ER/Trauma or operating room environment.

Computed Tomography

Featured at RSNA are BodyTom® Elite and OmniTom® – mobile whole-body and head CTs. These mobile CTs can be used at the point of care, whenever imaging is needed to determine the ideal treatment strategy for a patient – without restrictions of physical space and power. Samsung’s NeuroLogica mobile CT devices are used by numerous leading institutions in intensive care units, emergency rooms, orthopedic and neurosurgery rooms, brachytherapy suites and ambulances.

In addition, Samsung will be presenting a Photon Counting Detector (PCD)² – cutting-edge technology that measures photons emitted by X-rays. The PCD, currently under development, has the potential to allow for dose optimization, allowing the user to reduce exposure while maintaining image quality, or increase the image quality by keeping dose equivalence compared to currently used CT detectors. The PCD is expected to deliver increased data mining capabilities from multiple-energy detection and contribute to the improved utility and efficacy of AI applications. Expanding from this, Samsung is closely collaborating with a major university hospital in the United States.

Samsung will host three Industry Sessions during RSNA:

• Featured Demonstration about advanced imaging technologies with RS85 Prestige will be held on December 3, from 5:00 p.m. CT - 5:30 p.m. CT.
• AI Theater Presentation: Application of On-Device AI in Healthcare, in collaboration with Intel³, will discuss On-Device AI solutions that provide real-time feedback on ultrasound images and protect patients’ personal information. As a part of this collaboration, Samsung will host an Industry Session to address the differences between Cloud AI and On-Device AI, and the significance in ultrasound, available on demand throughout the duration of RSNA.
• Innovation Theater will highlight the performance of Auto Lung Nodule Detection (ALND)⁴ imaging application on chest radiographs of COVID-19 patients, available on demand throughout the duration of RSNA.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com.

About Samsung Medison

Samsung Medison is a global leading medical device company, founded in 1985. With a mission to bring health and well-being of people's lives, the company manufactures diagnostic ultrasound systems around the world across various medical fields. In 2011, Samsung Medison became an affiliate company of Samsung Electronics, integrating world's best IT, image processing, semiconductor and communication technologies into medical devices.

About NeuroLogica

NeuroLogica, the healthcare subsidiary of Samsung Electronics Co., Ltd., develops, manufactures, and markets innovative imaging technologies and is committed to delivering fast, easy and accurate diagnostic solutions to healthcare providers. NeuroLogica, the global corporate headquarters and manufacturer of mobile computed tomography, is also the US headquarters for sales, marketing and distribution of all Samsung digital radiography and ultrasound systems. NeuroLogica’s growing portfolio of advanced medical technologies is used worldwide in leading healthcare institutions helping providers enhance patient care, improve patient satisfaction, and increase workflow efficiency. For more information, please visit http://www.NeuroLogica.com.

¹ The S-Vue™ outcome is based on limited phantom and clinical study results. Only routine PA chest radiography and abdominal radiography for average adults and pediatric abdominal, chest, skull radiography were studied, excluding pediatric patients under 1 month old. (FDA cleared - K172229, K182183) In practice, the values of dose reduction may vary accordingly.

² Product is under development and not available for sale in USA or any region of the world.

³ Intel, the Intel logo, and other Intel marks are trademarks of Intel Corporation or its subsidiaries.

⁴ ALND is not available for commercial sale in the USA.